Literature DB >> 6424276

Mechanism of altered drug binding to serum proteins in pregnant women: studies with valproic acid.

R Riva, F Albani, M Contin, A Baruzzi, M Altomare, G P Merlini, E Perucca.   

Abstract

The mechanism underlying the impaired serum protein binding of valproic acid (VPA) in pregnancy was examined in samples collected from 24 healthy women in the last 3 weeks of gestation and 15 age-matched nonpregnant female controls. Experiments were performed in vitro using a rapid equilibrium dialysis technique free from in vitro alterations in free fatty acids (FFA). At a total drug concentration of approximately 420 mumol/L, the free VPA fraction was 10.2 +/- 2.9% (SD) in pregnant women and 4.8 +/- 1.0% in controls (p less than 0.001). Pregnancy was associated with a marked reduction in serum albumin levels but with only a slight, nonsignificant elevation in FFA. Free VPA fraction was negatively correlated with serum albumin levels. A positive correlation between free VPA fraction and FFA was observed in the pregnant group but not in the controls. The only sample collected during labour showed a striking elevation of both free VPA fraction and FFA, in spite of a normal albumin concentration. Scatchard's plots showed VPA bound to two classes of binding sites on the albumin molecule. The number of primary (n1) and secondary (n2) binding sites in pregnant women (n1 = 2.0; n2 = 10.7) was virtually identical to that observed in the controls (n1 = 1.9; n2 = 9.8). The association constants of the primary (k1) and secondary (k2) sites were lower in pregnant women (15.9 X 10(3) and 0.19 X 10(3) L/mol, respectively, vs. 22.6 X 10(3) and 0.33 X 10(3) L/mol in controls) but the difference was not significant.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6424276     DOI: 10.1097/00007691-198403000-00006

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  6 in total

1.  Nonlinear binding of valproic acid (VPA) and E-delta 2-valproic acid to rat plasma proteins.

Authors:  R L Semmes; D D Shen
Journal:  Pharm Res       Date:  1990-05       Impact factor: 4.200

Review 2.  Pharmacotherapy for mood disorders in pregnancy: a review of pharmacokinetic changes and clinical recommendations for therapeutic drug monitoring.

Authors:  Kristina M Deligiannidis; Nancy Byatt; Marlene P Freeman
Journal:  J Clin Psychopharmacol       Date:  2014-04       Impact factor: 3.153

3.  Pharmacokinetics of total and free valproic acid during monotherapy in infants.

Authors:  L Herngren; B Lundberg; A Nergårdh
Journal:  J Neurol       Date:  1991-09       Impact factor: 4.849

Review 4.  Clinical pharmacokinetics of valproic acid--1988.

Authors:  G Zaccara; A Messori; F Moroni
Journal:  Clin Pharmacokinet       Date:  1988-12       Impact factor: 6.447

Review 5.  Pharmacokinetics of valproate in pregnancy: mother-foetus-newborn.

Authors:  S I Johannessen
Journal:  Pharm Weekbl Sci       Date:  1992-06-19

Review 6.  Insights into Structural Modifications of Valproic Acid and Their Pharmacological Profile.

Authors:  Manish Kumar Mishra; Samiksha Kukal; Priyanka Rani Paul; Shivangi Bora; Anju Singh; Shrikant Kukreti; Luciano Saso; Karthikeyan Muthusamy; Yasha Hasija; Ritushree Kukreti
Journal:  Molecules       Date:  2021-12-24       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.